Evidence map›Paper›PMID 31537996›Full record

ArticleBone & joint research2019

Safety assessment of microsilver-loaded poly(methyl methacrylate) (PMMA) cement spacers in patients with prosthetic hip infections: Results of a prospective cohort study.

Volker Alt, Markus Rupp, Karsten Lemberger, Thorsten Bechert, Thomas Konradt, Peter Steinrücke, Reinhard Schnettler, Stephan Söder, Rudolf Ascherl

Open access · goldAbstract read
In one paragraph

Article in Bone & joint research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Volker AltDepartment of Trauma Surgery, University Hospital Regensburg, Regensburg, Germany.
Markus RuppDepartment of Trauma, Hand and Reconstructive Surgery, University Hospital Giessen-Marburg, Campus Giessen, Giessen, Germany.
Karsten LembergerDepartment of Orthopaedics, Trauma Surgery and Sports Medicine, Asklepios Klinik Birkenwerder, Birkenwerder, Germany.
Thorsten BechertBio-Gate AG, Nuremberg, Germany.
Thomas KonradtBio-Gate AG, Nuremberg, Germany.
Peter SteinrückeBio-Gate AG, Nuremberg, Germany.
Reinhard SchnettlerDepartment of Cranio-Maxillo-Facial Surgery, University Hospital Hamburg, Hamburg, Germany.
Stephan SöderInstitute of Pathology, Regiomed Hospital, Coburg, Germany.
Rudolf AscherlHospital for Traumatology, Special Surgery and Revision Endoprosthetic Surgery, Tirschenreuth, Germany.
Advanced Life Technologies (United States) · USPark-Klinik Birkenwerder · DERegio (Germany) · DEUniversität Hamburg · DEUniversitätsklinikum Gießen und Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPreclinical data showed poly(methyl methacrylate) (PMMA) loaded with microsilver to be effective against a variety of bacteria. The purpose of this study was to assess patient safety of PMMA spacers with microsilver in prosthetic hip infections in a prospective cohort study.

methodsA total of 12 patients with prosthetic hip infections were included for a three-stage revision procedure. All patients received either a gentamicin-PMMA spacer (80 g to 160 g PMMA depending on hip joint dimension) with additional loading of 1% (w/w) of microsilver (0.8 g to 1.6 g per spacer) at surgery 1 followed by a gentamicin-PMMA spacer without microsilver at surgery 2 or vice versa. Implantation of the revision prosthesis was carried out at surgery 3.

resultsIn total, 11 of the 12 patients completed the study. No argyria or considerable differences in laboratory parameters were detected. Silver blood concentrations were below or around the detection limit of 1 ppb in ten of the 11 patients. A maximum of 5.6 ppb at 48 hours after implantation of the silver spacer, which is below the recommended maximum level of 10 ppb, was found in one patient. No silver was detected in the urine. Drainage fluids showed concentrations between 16.1 ppb and 23.3 ppb at 12 hours after implantation of the silver spacers, and between 16.8 ppb to 25.1 ppb at 48 hours after implantation. Pathohistological assessment of the periprosthetic membrane did not reveal any differences between the two groups.

conclusionMicrosilver-loaded gentamicin-PMMA spacers showed good biocompatibility and the broad antimicrobial activity warrants further clinical research to assess its effectivity in reducing infection rates in prosthetic joint infection.

Indexed as

HipPoly(methyl methacrylate)Prosthetic infectionSilverSpacer

Identifiers

PMID31537996
PMCPMC6719530
OpenAlexW2978856871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.